Abstract: The mature rheumatoid arthritis (RA) market boasts ten different biologics representing several distinct drug classes, including blockbuster tumor necrosis factor alpha (TNF-α)…
Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used throughout the course of disease…
Introduction: This research explores the reimbursement and utilization landscape for anti-osteoporotic drugs. The osteoporosis market is characterized by the availability of low-cost generic oral…
AD is a chronic inflammatory skin disease marked by pruritus, eczema, and, in moderate to severe patients, frequent relapse. Standard AD treatments aim to protect the skin barrier through…
In the past decade, tumor necrosis factor-alpha (TNF-α) inhibitors, AbbVie’s Humira and Amgen’s Enbrel, and Janssen’s interleukin (IL)-12/23 inhibitor Stelara have been leading the U.S…
Obesity is a growing epidemic in the United States. Despite the high prevalence, only a limited number of antiobesity drugs are available, and lifestyle interventions remain the cornerstone of…
Antineoplastic treatment in stage IV renal cell carcinoma is with targeted agents. The market entry of an immune checkpoint inhibitor has revolutionized the treatment algorithm for previously…
Although TNF-α inhibitors and other RA biologics are generally considered efficacious and safe and adequately control disease in many conventional DMARD-refractory RA patients, therapies that are…
As the prevalence of chronic pain associated with numerous indications (e.g., osteoarthritis, cancer) and of idiopathic origin (e.g., chronic back pain) continues to increase in the United States…
The treatment of breast cancer has a rich and diverse product pipeline and continues to be one of the most lucrative and active areas of research in oncology. However, the barriers to entry are…
Adult OM/PJI due to MRSA are among the most hard-to-treat MRSA infections due to the difficulties for the body’s natural infection-fighting cells and antibiotics to reach the infected tissues in…
In the context of growing healthcare costs, vaccines stand out as highly cost-effective products for improving public health. Furthermore, compared with pharmaceuticals, vaccines tend to carry a…
Nearly 35 years after the Orphan Drug Act of 1983 (ODA) became law in the United States, private investment in the development of drugs for orphan diseases continues unabated. Although the growing…
Pancreatic cancer remains a deadly disease with limited treatment options. In the first-line setting, the current standards of care (SOCs) are FOLFIRINOX and Celgene’s Abraxane, while in the…
The malignant melanoma therapy market is emerging from a very dynamic period (notably 2011-2015) characterized by a plethora of new drug approvals and label expansions. The approvals of both immune…
